WebJun 16, 2024 · BMS 986141 is a small-molecule platelet thrombin receptor antagonist selective for the protease-activated receptor-4 (PAR4), that was being developed by … WebMar 29, 2024 · BMS-986120 is a novel anti-platelet agent that antagonises protease-activated receptor type 4 (PAR-4) and may have a more favourable anti-thrombotic and bleeding profile. Hypothesis: BMS-986120 will reduce human thrombus formation in an ex vivo (Badimon) perfusion model.
BMS-986120 CAS 1478712-37-6 AbMole BioScience BMS-986120 …
WebCandidates (BMS-986120 and BMS-986141) that Antagonize Protease-Activated Receptor 4 E. Scott Priestley,* 1 Jacques Banville,2 Daniel Deon, 2 Laurence Dubé, 2 Marc Gagnon, 2 Julia Guy, 2 Philippe Lapointe, 2 Jean-François Lavallée, 2 Alain Martel,2 Serge Plamondon, 2 Roger Rémillard, 2 Edward Ruediger, 2 François Tremblay, 2 Shana L. … WebIntroduction: BMS-986120 (BMS) is a novel orally-active antagonist of protease-activated receptor-4 (PAR4), a human platelet thrombin receptor, and is in phase I clinical trial. … rjr software
Abstract 175: A Novel Orally-Active Small-Molecule
WebDec 21, 2024 · BMS-986120 is a first-in-class, oral, highly selective, and reversible PAR4 antagonist antiplatelet agent. A single dose of BMS-986120 substantially reduced ex vivo thrombus formation in healthy volunteers under conditions of high shear stress, driven by a reduction in platelet-rich thrombus deposition. WebBMS-986120 is a novel first-in-class oral protease-activated receptor 4 (PAR4) antagonist exhibiting robust antithrombotic activity that has shown low bleeding risk in monkeys. We sought to assess pharmacokinetics, pharmacodynamics, and tolerability of BMS-986120 in healthy participants and platelet … WebJan 5, 2024 · Researchers say they have developed an antiplatelet agent that has demonstrated considerable antithrombotic activity and low bleeding liability in monkeys. The agent, known as BMS-986120, is a PAR4 antagonist. smpt host